Wang, J., Gao, J., Msaouel, P., Sharma, P., Tannir, N., Subudhi, S. K., . . . Siefker-Radtke, A. O. (2021). Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. BMJ Publishing Group.
Chicago Style (17th ed.) CitationWang, Jennifer, et al. Durable Responses in Patients with Genitourinary Cancers Following Immune Checkpoint Therapy Rechallenge After Moderate-to-severe Immune-related Adverse Events. BMJ Publishing Group, 2021.
MLA (8th ed.) CitationWang, Jennifer, et al. Durable Responses in Patients with Genitourinary Cancers Following Immune Checkpoint Therapy Rechallenge After Moderate-to-severe Immune-related Adverse Events. BMJ Publishing Group, 2021.
Warning: These citations may not always be 100% accurate.